BMRN - バイオマリン・ファ―マシュ―ティカルズ （BioMarin Pharmaceutical Inc.） バイオマリン・ファ―マシュ―ティカルズBMRNのチャート
BMRNの企業情報
| symbol | BMRN |
|---|---|
| 会社名 | BioMarin Pharmaceutical Inc. （バイオマリン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 バイオマリン・ファーマスーティカル（BioMarin Pharmaceutical Inc.）はバイオテクノロジ企業である。同社はさまざまな病気や病状に対して医薬品の開発と商業化を行う。2016年12月31日現在、同社の治療ポートフォリオは五つの承認医薬品、複数の臨床および前臨床製品候補から構成される。同社の承認医薬品はムコ多糖症I（MPS I）向けのアルデュラザイム（ラロニダーゼ）、ランバートイートン重症筋症（LEMS）向けのファーデサル（リン酸アミンピリジン）、フェニルケトン尿症（PKU）向けのクワン（サプロプテリン二塩酸塩）、ムコ多糖症VI（MPS VI）向けのナガラザイム（ガルスルファイゼ）、ムコ多糖症IV型A（MPS IV A）向けのVimizim （elosulfase alpha）などを含む。同社の臨床候補薬はBrineura、pegvaliase、vosoritide、BMN 270とBMN 250を含む。 バイオマリン・ファ―マシュ―ティカルズは、米国の医薬品メ―カ―。主製品は承認薬5品：ムコ多糖症I治療薬Aldurazyme、ムコ多糖症VI治療薬Naglazyme、フェニルケトン尿症治療薬Kuvan、ランバ―トイ―トン筋無力症候群治療薬Firdapse、ムコ多糖症IV・モルキオ症候群タイプA・リソソ―ム蓄積障害治療薬VIMIZIM。 BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. |
| 本社所在地 | 770 Lindaro Street San Rafael CA 94901 USA |
| 代表者氏名 | Jean-Jacques Bienaime ジャン=ジャックビエナイム |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 415-506-6700 |
| 設立年月日 | 35339 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1999年 |
| 従業員数 | 2581人 |
| url | www.biomarin.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bmrn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -87.42600 |
| 終値（lastsale） | 101.39 |
| 時価総額（marketcap） | 18005888222.64 |
| 時価総額 | 時価総額（百万ドル） 18517.35 |
| 売上高 | 売上高（百万ドル） 1438.745 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 18345.9 |
| 当期純利益 | 当期純利益（百万ドル） -87.16000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioMarin Pharmaceutical Inc. revenues increased 20% to $746.3M. Net loss before extraordinary items increased 23% to $65.5M. Revenues reflect United States segment increase of 29% to $353.4M Europe segment increase of 36% to $178.6M. Higher net loss reflects Research and development - Balancing val increase of 26% to $330.7M (expense) Selling General and Admin - Bal Val increase of 13% to $259.4M (expense). |
BMRNのテクニカル分析
BMRNのニュース
Explosive growth on Hemophilia A Treatment Market 2021-2027: Global Companies like CSL Behring, Pfizer, Bayer, BioMarin, Genzyme, Chugai Pharma 2021/10/04 10:51:33 OpenPR
Overview of Global Hemophilia A Treatment Market: With an international Hemophilia A Treatment Market report, businesses will come to know current and future of Market outlook in the developed and emerging Markets. The report provides analysis of various perspectives of the
Hereditary Testing Market 2021-2027 | Latest COVID19 Impact Analysis | Know About Brand Players: Roche, Abbott, Amgen, Pfizer, BioMarin, Sanofi, Takeda 2021/09/28 10:30:58 OpenPR
Overview of Global Hereditary Testing Market: Todays businesses choose the market research report solution such as Hereditary Testing Market report because it lends a hand with the improved decision making and more revenue generation. The report also aids in prioritizing Market
Phenylketonuria (PKU) Market Research Report 2021 Challenges and General Business Research to 2027|Biomarin, Mead Johnson, Abbott, Nutricia, Dr. Schr 2021/09/14 09:21:57 OpenPR
The report titled Global Phenylketonuria (PKU) MARKET is one of the most comprehensive and important additions to market research studies. It offers detailed research and analysis of key aspects of the Phenylketonuria (PKU) market. The market analysts authoring this report
BioMarin upgraded by Stifel to Buy on potential FDA nod for dwarfism drug 2021/09/09 15:17:19 Seeking Alpha
Thursdays Top Analyst Upgrades and Downgrades: Baker Hughes, BioMarin, Cisco, Haliburton, Macys, Schlumberger, Sherwin-Williams and More 2021/09/09 12:55:27 24/7 Wall street
Exclusive Research Report On Hemophilia Treatment Market 2021. Major Players CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, etc. 2021/07/07 11:30:41 Tramways Monthly
DataIntelo has released their new Hemophilia Treatment Market research report and forecasts for the industry for next eight years. The company predicts that by 2028, there will be a XX% increase in global demand and market will grow with a CAGR of XX%. With this forecast, the future of Hemophilia Treatment market looks bright. The []
BioMarin resubmits haemophilia A gene therapy to the EMA - PharmaTimes 2021/07/03 16:32:01 The Pharma Times
Company initially withdrew a marketing authorisation application for the gene therapy last year
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress 2021/07/02 13:05:00 Investors Biomarin
Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemophilia A
Canada: Plaintiff Cannot Amend Statement Of Claim More Than 45 Days After Receipt Of NOAs To Plead Infringement Of Further Patents - Smart & Biggar 2021/07/02 11:11:38 Mondaq
On May 5, 2021, the Federal Court dismissed a motion by Biomarin Pharmaceutical Inc (Biomarin) to amend its Statement of Claim to allege infringement of two patents that had not been asserted
Batten Disease Treatment Market (2021-2027) | Latest COVID19 Impact Analysis | Know About Brand Players: Abeona Therapeutics Inc., BioMarin Pharmaceutical Inc., CereSpir Inc., Evotec AG, Ionis Pharmaceuticals Inc., Mitochon Pharmaceuticals Inc., and Spark 2021/07/01 07:51:57 OpenPR
Precision Business Insights published a research report on "Batten Disease Treatment Market by Type of disease (Juvenile NCL (JNCL), Infantile NCL (INCL), Late infant NCL (LINCL), Adult NCL, Others), Treatment (Gene Therapy, Drug Therapy, Enzyme Therapy, Others), Distribution channel (Hospital
BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II 2021/06/22 12:17:21 FierceBiotech
BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II badams Tue, 06/22/2021 - 08:17
Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy? 2021/06/21 16:17:50 Yahoo Finance
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually dont make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are []
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors 2021/06/14 10:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)---- $AUPH--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Companys Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (BioMarin), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and li